Literature DB >> 12039880

Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.

Heather J Smith1, Kimberly A Nichol, Daryl J Hoban, George G Zhanel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12039880     DOI： 10.1093/jac/dkf047

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  13 in total

1.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

Authors:  Y Claire Wang; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

3.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.

Authors:  Jacob Strahilevitz; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

Authors:  Nataliya Korzheva; Todd A Davies; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Factor analysis of microbiological activity data and structural parameters of antibacterial quinolones.

Authors:  Marcin Koba; Tomasz Baczek; Katarzyna Macur; Leszek Bober; Teresa Frackowiak; Adam Buciński; Danuta Rystok-Grabska; Jolanta Stasiak; Katarzyna Koba
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

7.  Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Authors:  F Wagenlehner; M Nowicki; C Bentley; M Lückermann; S Wohlert; C Fischer; A Vente; K Naber; A Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 8.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 9.  Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Authors:  Cristian Jivcu; Mark Gotfried
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03

10.  Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.

Authors:  Samir N Patel; Roberto Melano; Allison McGeer; Karen Green; Donald E Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-18       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.